Clinical Trial Update: Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating abaloparatide (BA058) for prevention of fractures in postmenopausal osteoporosis has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Abaloparatide (abaloparatide)

Snippet

Sponsor: Radius Health, Inc. | Conditions: Osteoporosis, Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2017-03-01